{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-290768","form_type":"8-K","ticker":"CPRX","cik":"0001369568","company_name":"CATALYST PHARMACEUTICALS, INC.","filed_at":"2026-06-30T20:57:55+00:00","discovered_at":"2026-06-30T20:59:00.285492+00:00","generated_at":"2026-06-30T20:59:03.821352+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Catalyst Pharma: Vamorolone Phase 1 shows glucocorticoid activity without immunosuppression at clinical doses","bullets":["Phase 1 study: vamorolone 300 mg vs deflazacort 0.9 mg/kg showed comparable cortisol suppression.","No significant immunosuppressive effects at clinical doses (9 or 27 mg/kg/day); only at 40 mg/kg/day.","Data support current vamorolone dosing in DMD and potential for broader chronic inflammatory indications.","Study enrolled 24 healthy adults (Part A) and 36 volunteers (Part B) with ascending doses."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-290768","json":"https://secwatch.observer/filing/0001193125-26-290768.json","markdown":"https://secwatch.observer/filing/0001193125-26-290768.md","text":"https://secwatch.observer/filing/0001193125-26-290768.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369568/000119312526290768/0001193125-26-290768-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369568/000119312526290768/d158010d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T20:59:03.821352+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}